Telefield Medical Imaging has been selected for the Forbes Asia 100 to Watch 2023 list which was released on August 29.
A drought in global venture capital activity has not deterred startups across Asia from breaking new ground. This year’s Forbes Asia 100 to Watch list spotlights small companies and startups that are targeting underserved markets or applying new technologies. Thirteen countries and territories are represented across 11 categories, including biotechnology and healthcare, e-commerce and retail, and finance. Leading the list for the second year in a row, Singapore contributed 20 companies to the list, followed by Hong Kong with 15 and mainland China with 11.
To select 100 to Watch, Forbes Asia solicited online submissions, and invited accelerators, incubators, SME advocacy organizations, universities, venture capitalists and others to nominate companies as well. The final 100 were selected from over 550 submissions. Forbes Asia evaluated each submission, looking at metrics such as a positive impact on the region or industry, a track record of strong revenue growth or ability to attract funding, promising business models or markets, and a persuasive story.
Telefield Medical Imaging has been ranked among “Asia-Pacific’s small companies and startups on the rise” by the Forbes Asia 100 to Watch 2023 list for our flagship Scolioscan, which is the first of its kind in the world. Scolioscan integrates ultrasound, artificial intelligence and positioning technologies to achieve radiation-free and three-dimensional imaging of the spine.
Founded in 2012, Telefield Medical Imaging is headquartered in Hong Kong and committed to alleviating scoliosis. On the strength of pioneering technologies, we provide radiation-free spine imaging and assessment throughout the screening, diagnosis and treatment of scoliosis. We’ve raised $13 million in funding, with support from Alibaba Entrepreneurs Fund, Chindex Medical, Fosun Pharma, Gobi Partners, Hong Kong Polytechnic University, and Hong Kong Science Park.
Scolioscan has been tested in clinical trials and used in hospitals and clinics in China, Germany, Poland, Italy, Bosnia, Romania, the Netherlands, Australia and Malaysia, prompting the early detection, early treatment, and early recovery of scoliosis worldwide.
Learn more about the list: